Related Experiment Video
Updated: Jul 13, 2025

Aip1p Dynamics Are Altered by the R256H Mutation in Actin
Published on: July 30, 2014
Annexin A2 Stabilizes Oncogenic JAG1 Intracellular Domain by Inhibiting Proteasomal Degradation in Glioblastoma Cells
Seok Won Ham1,2,3, Jung Yun Kim1,2, Sunyoung Seo1,2
1Department of Biotechnology, College of Life Sciences and Biotechnology, Korea University, Seoul 02841, Republic of Korea.
Abstract:
Glioblastoma (GBM) is the most lethal brain cancer, causing inevitable deaths of patients owing to frequent relapses of cancer stem cells (CSCs). The significance of the NOTCH signaling pathway in CSCs has been well recognized; however, there is no NOTCH-selective treatment applicable to patients with GBM. We recently reported that Jagged1 (JAG1), a NOTCH ligand, drives a NOTCH receptor-independent signaling pathway via JAG1 intracellular domain (JICD1) as a crucial signal that renders CSC properties. Therefore, mechanisms regulating the JICD1 signaling pathway should be elucidated to further develop a selective therapeutic regimen. Here, we identified annexin A2 (ANXA2) as an essential modulator to stabilize intrinsically disordered JICD1. The binding of ANXA2 to JICD1 prevents the proteasomal degradation of JICD1 by heat shock protein-70/90 and carboxy-terminus of Hsc70 interacting protein E3 ligase. Furthermore, JICD1-driven propagation and tumor aggressiveness were inhibited by ANXA2 knockdown. Taken together, our findings show that ANXA2 maintains the function of the NOTCH receptor-independent JICD1 signaling pathway by stabilizing JICD1, and the targeted suppression of JICD1-driven CSC properties can be achieved by blocking its interaction with ANXA2.
Insights
Annexin A2 (ANXA2) stabilizes the Jagged1 intracellular domain (JICD1), crucial for glioblastoma stem cell properties. Blocking ANXA2 interaction with JICD1 inhibits tumor growth, offering a potential therapeutic strategy for brain cancer.
Area of Science:
- Neuro-oncology
- Molecular Biology
- Cancer Stem Cell Research
Background:
- Glioblastoma (GBM) is an aggressive brain cancer with high mortality, often driven by relapsing cancer stem cells (CSCs).
- The NOTCH signaling pathway is implicated in CSCs, but targeted therapies for GBM remain limited.
- Jagged1 (JAG1) intracellular domain (JICD1) activates a NOTCH-independent pathway, promoting CSC properties.
Purpose of the Study:
- To elucidate the regulatory mechanisms of the JICD1 signaling pathway.
- To identify key modulators involved in JICD1 stabilization and function.
- To explore therapeutic strategies targeting the JICD1 pathway in GBM.
Main Methods:
- Identification of proteins interacting with JICD1 using biochemical assays.
- Assessment of JICD1 stability and degradation pathways.
- Evaluation of ANXA2 knockdown effects on JICD1 signaling, CSC properties, and tumor aggressiveness in GBM models.
Main Results:
- Annexin A2 (ANXA2) was identified as a critical protein that stabilizes JICD1.
- ANXA2 binding prevents JICD1 proteasomal degradation mediated by HSP70/90 and CHIP.
- ANXA2 knockdown significantly inhibited JICD1-driven GBM propagation and aggressiveness.
- Targeting the ANXA2-JICD1 interaction suppressed JICD1-mediated CSC properties.
Conclusions:
- ANXA2 stabilizes JICD1, maintaining the NOTCH-independent signaling pathway essential for GBM stem cell function.
- The ANXA2-JICD1 interaction represents a potential therapeutic target for suppressing glioblastoma stem cell properties and tumor progression.
More Related Videos
Related Concept Videos
The Intrinsic Apoptotic Pathway
Intracellular Signaling Affects Focal Adhesions
Some...
The JAK-STAT Signaling Pathway
Anaphase Promoting Complex
Cancer Cell Migration through Invadopodia
The Extrinsic Apoptotic Pathway

